Related Experiment Video
Updated: Jul 19, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Potentiation of antiglioma effect with combined temozolomide and interferon-beta
Jin-A Park1, Young-Ae Joe, Tai-Gyu Kim
1Department of Neurosurgery, The Catholic University of Korea, Seoul 137-701, Korea.
Abstract:
Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma. Interferon-beta (IFN-beta) is known to have antiproliferative and antiangiogenic activities. The aim of this study was to elucidate whether an antiglioma effect could be potentiated by the combination of TMZ and IFN-beta. In vitro, the combination of these drugs suppressed the proliferative and migratory activities, as well as enhance of the apoptosis and cell cycle (S phase) arrest of U-87 cells more efficiently than TMZ or IFN-beta alone. IFN-beta exerted a potent inhibitory effect on the proliferation of human umbilical vein endothelial cells (HUVEC); however, no additive or synergistic effect was observed with the addition of TMZ. To determine in vivo effect, nude mice bearing intracerebral U-87 xenograft inoculation were treated with intraperitoneal administration of PBS, TMZ (15 mg/kg for 3 days), IFN-beta (2x10(5) IU for 15 days), and a TMZ + IFN-beta combination. The combined treatment (median 62.0+/-8.6 days, P=0.0005) was observed to significantly increase the survival of the animals compared to treatment with PBS (median 30.0+/-2.5 days), TMZ (median 41.0+/-3.5 days) or IFN-beta (mean 36.0+/-2.5 days). These results suggest that antiglioma activity can be enhanced by the combination of TMZ and IFN-beta, providing the possibility for a new strategy development in the management of malignant glioma.
Insights
Combining temozolomide (TMZ) and interferon-beta (IFN-beta) significantly enhances antiglioma effects. This combination therapy shows improved survival in preclinical models, suggesting a promising new strategy for malignant glioma treatment.
Area of Science:
- Neuro-oncology
- Cancer Pharmacology
- Immunotherapy
Background:
- Temozolomide (TMZ) is a DNA methylating agent with antitumor activity against high-grade glioma.
- Interferon-beta (IFN-beta) exhibits antiproliferative and antiangiogenic properties.
Purpose of the Study:
- To investigate the potential potentiation of antiglioma effects through the combination of TMZ and IFN-beta.
- To evaluate the combined efficacy of TMZ and IFN-beta in preclinical models of glioma.
Main Methods:
- In vitro studies assessed the effects of TMZ and IFN-beta on U-87 glioma cells and human umbilical vein endothelial cells (HUVEC).
- In vivo efficacy was determined using nude mice with intracerebral U-87 xenografts treated with PBS, TMZ, IFN-beta, or the combination.
Main Results:
- The combination of TMZ and IFN-beta demonstrated superior suppression of proliferation, migration, and enhanced apoptosis and cell cycle arrest in U-87 cells compared to monotherapy.
- IFN-beta inhibited HUVEC proliferation, but no additive or synergistic effect was observed with TMZ.
- Combined TMZ and IFN-beta treatment significantly increased median survival in mice bearing U-87 xenografts (62.0 days) compared to PBS (30.0 days), TMZ (41.0 days), or IFN-beta (36.0 days).
Conclusions:
- The combination of temozolomide and interferon-beta enhances antiglioma activity.
- This combination therapy offers a potential new strategy for managing malignant glioma.
- Further clinical investigation into TMZ and IFN-beta combination therapy is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers